CAM
TPST icon

Cormorant Asset Management’s Tempest Therapeutics TPST Stock Holding History

Cormorant Asset Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-86
Closed -$2.39M – 89
2016
Q1 		$2.39M Hold
86
– – 0.36% 61
2015
Q4 		$2.46M Hold
86
– – 0.29% 59
2015
Q3 		$2.14M Hold
86
– – 0.34% 56
2015
Q2 		$7.3M Sell
86
-72
-46% -$6.6M 0.97% 32
2015
Q1 		$16.1M Sell
158
-97
-38% -$12.9M 2.48% 12
2014
Q4 		$33M Buy
255
+79
+45% +$5.79M 5.09% 4
2014
Q3 		$8.57M Buy
+176
New +$6.17M 1.76% 12

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
CQS Cayman Camana Bay, Grand Cayman, Cayman Islands $2.26B AUM 1.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Cormorant Asset Management's TPST Position: Q2 2016 in Review

Cormorant Asset Management sold out of Tempest Therapeutics (TPST) in Q2 2016, closing a stake of 86 shares — an estimated $2.39M sold.

Cormorant Asset Management first reported a position in TPST in Q3 2014 and held it in 7 quarters. The position peaked at $33M in Q4 2014. 85 funds tracked by Wall St. Rank hold TPST as of Q2 2016.

  • Cormorant Asset Management reported no remaining Tempest Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Cormorant Asset Management sold 86 Tempest Therapeutics shares in Q2 2016, an estimated $2.39M.
  • Cormorant Asset Management first reported a position in Tempest Therapeutics in Q3 2014 and held it in 7 quarters.
  • Cormorant Asset Management's Tempest Therapeutics position peaked at $33M in Q4 2014.
  • 85 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2016.

Based on Cormorant Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.